Cyclezyme AB (XSAT:CYCLE) ROCE %: -43.85% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CYCLE Cyclezyme AB XSAT:CYCLE
8 GF Score
Price kr23.90
! 3 Warning Signs
View Full Analysis

What is Cyclezyme AB ROCE %?

Cyclezyme AB XSAT:CYCLE -2.05% 8 ROCE % is -43.85% as of Mar. 2026. GuruFocus rates XSAT:CYCLE with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Cyclezyme AB's annualized ROCE % for the quarter that ended in Mar. 2026 was -43.85%.

Cyclezyme AB  (XSAT:CYCLE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Cyclezyme AB ROCE % Related Terms

Cyclezyme AB ROCE % Historical Data

* Premium members only.

The historical data trend for Cyclezyme AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyclezyme AB ROCE % Chart

Cyclezyme AB Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial -85.54 -118.39 -33.14 -33.31 -23.55

Cyclezyme AB Quarterly Data
Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.34 -46.58 -26.38 -4.81 -43.85
XSAT:CYCLE
8GF Score
Cyclezyme AB XSAT:CYCLE
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cyclezyme AB ROCE % Calculation

Cyclezyme AB's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-1.538/( ( (5.804 - 0.699) + (8.636 - 0.678) )/ 2 )
=-1.538/( (5.105+7.958)/ 2 )
=-1.538/6.5315
=-23.55 %

Cyclezyme AB's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-3.3/( ( (8.636 - 0.678) + (7.975 - 0.881) )/ 2 )
=-3.3/( ( 7.958 + 7.094 )/ 2 )
=-3.3/7.526
=-43.85 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -43.85% mean?
Cyclezyme AB (XSAT:CYCLE) has a ROCE % of -43.85% as of Mar. 2026.
Is Cyclezyme AB's ROCE % too high?
Cyclezyme AB's current ROCE % is -43.85%. Overall, Cyclezyme AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Cyclezyme AB's ROCE % compare to LIN and SHW?
Cyclezyme AB's ROCE % of -43.85% can be compared against companies in the Chemicals industry. The industry median ROCE % is 6.49. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Chemicals company?
The median ROCE % among Chemicals companies is 6.49, based on 1,588 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median ROCE % is 6.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclezyme AB's current ROCE % is -43.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclezyme AB stock overvalued right now?
Cyclezyme AB (XSAT:CYCLE) has a current ROCE % of -43.85%. The current ROCE % is -43.85%. Cyclezyme AB's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Cyclezyme AB (XSAT:CYCLE), the current ROCE % is -43.85% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyclezyme AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
8GF Score

Get the complete analysis for XSAT:CYCLE

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.90
Price